Voyager Therapeutics (VYGR) PT Raised to $19 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Voyager Therapeutics (VYGR) Shares Jump 40% After Announcing Pact with Neurocrine Biosciences
January 29, 2019 7:16 AM ESTVoyager Therapeutics (NASDAQ: VYGR) shares jumped 40% after Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager announced the formation of a strategic collaboration focused on the development and commercialization of Voyagers gene therapy programs, VY-AADC for Parkinsons... More
Neurocrine Biosciences (NBIX) and Voyager Therapeutics (VYGR) Announces Pact for Parkinson’s Disease and Friedreich’s Ataxia
January 29, 2019 7:07 AM ESTNeurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR), today announced the formation of a strategic collaboration focused on the development and commercialization of Voyagers gene therapy programs, VY-AADC for Parkinsons disease and VY-FXN01 for Friedreichs ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences expertise in neuroscience, drug development and commercialization with Voyagers innovative gene therapy programs targeting severe neurological diseases.
Neurocrine Biosciences and Voyager will each host a company conference... More
